

Content

List of Abbreviations xiii

List of Figures..... xviii

List of Tables.....xx

1 Introduction..... 1

1.1 Glioma classification and standard therapy 1

1.2 Glioma immunity and immune cell suppression in the glioma microenvironment..... 2

1.3 Immunotherapy for glioma patients – present and perspective approaches 5

1.4 Immune checkpoints and immune checkpoint blockade 9

1.5 Immune checkpoint blockade for glioma patients 14

1.6 The GI261 glioma model 15

1.7 Aim of this study..... 16

2 Material and Methods 18

2.1 Cell culture..... 18

2.2 Mice 18

2.3 GI261 tumor injection and MR tumor monitoring 18

2.4 Immune checkpoint (ICB) therapy and response definition..... 19

2.5 *In vivo* antibodies and T cell depletion..... 19

2.6 GI261 tumor re-challenge..... 20

2.7 B16 tumor injection and tumor monitoring 20

2.8 Isolation of GI261- and B16-infiltrating lymphocytes 20

2.9 Isolation of splenocytes..... 21

2.10 Isolation of blood leukocytes and plasma preparation 21

2.11 Flow cytometry..... 21

2.12 Purification of T cells and myeloid cells 22

2.13 *Ex vivo* phagocytosis..... 23

2.14 *Ex vivo* T cell suppression assay..... 23

2.15	<i>Ex vivo</i> TIL cytotoxicity assay.....	24
2.16	Generation and polarization of bone marrow derived macrophages (BMDM).....	24
2.17	Regulatory phenotype and T cell suppression of CD80 Ig stimulated BMDM	25
2.18	Immunohistochemistry of GI261 brain tumors	26
2.19	Cytokine array and ELISA.....	26
2.20	Reverse transcription-quantitative PCR (RT-qPCR).....	27
2.21	Gene expression analysis	27
2.22	TCR β sequencing	27
2.23	Tumor cell exome sequencing and MHC-binding prediction.....	28
2.24	Patient material	29
2.25	Isolation of tumor-infiltrating lymphocytes from human glioma	29
2.26	Isolation of peripheral blood monocytic cells (PBMC).....	30
2.27	<i>Ex vivo</i> expansion of human glioma-infiltrating T cells.....	30
2.28	Graphical representations and statistical analysis	30
2.29	Material	31
2.29.1	Cell culture media.....	31
2.29.2	Buffer	32
2.29.3	Primer.....	32
2.29.4	Antibodies and dyes	33
2.29.5	Kits	37
3	Results	38
3.1	Resistance to immune checkpoint blockade targeting CTLA-4 and PD-1 in a syngeneic glioma model.....	38
3.1.1	Dual PD-1 and CTLA-4 blockade decreases GI261 tumor growth and induces long-term anti-tumor immunity in ICB responder mice	38
3.1.2	Resistance to PD-1 and CTLA-4 blockade is associated with increased intra-tumoral macrophage frequencies	41
3.1.3	TAMs of ICB non-responder mice express elevated levels of immunosuppressive markers.....	44

3.1.4	TAM frequencies and expression of immunosuppressive markers by TAMs negatively correlate with response to ICB	49
3.1.5	Suppressive macrophage phenotype of non-responder TAMs is specific to the glioma microenvironment.....	51
3.1.6	Response to ICB therapy is restored by blocking alternative mechanism of T cell suppression by PD-L1 expressing TAMs	53
3.1.7	PD-L1 signaling in TAMs does not alter <i>ex vivo</i> phagocytic activity	54
3.1.8	PD-L1 signaling in macrophages does not induce a regulatory phenotype	55
3.1.9	Tumor-associated myeloid cells of ICB non-responder suppress CD4 T cell proliferation	59
3.2	Identifying and exploiting tumor-reactive T cell subsets in experimental and human glioma	61
3.2.1	Response to ICB therapy is driven by tumor-reactive T cell subset	61
3.2.2	Identification of CD8 TCR β sequences and neo-epitopes associated with ICB response	62
3.2.3	Role of pre-existent and environmental factors in ICB therapy response	66
3.2.4	Presence and <i>ex vivo</i> reinvigoration of PD-1 ⁺ glioma TILs as a tool for the identification of tumor-reactive clones.....	68
4	Discussion	72
4.1	Resistance to immune checkpoint blockade targeting CTLA-4 and PD-1 in a syngeneic glioma model.....	72
4.1.1	Towards rational response evaluation for immunotherapy in glioma patients.....	72
4.1.2	TAM-mediated resistance to ICB therapy	73
4.1.3	The PD-L1/PD-1/CD80 axis and its role in resistance to ICB therapy	76
4.1.4	Inhibition and/or reprogramming of immunosuppressive TAMs: a promising combination for ICB therapy?	79
4.2	Identifying and exploiting tumor-reactive T cell subsets in experimental and human glioma	81
4.2.1	Exploiting ICB therapy as a tool to identify tumor-reactive T cells and tumor neo-epitopes.....	81

4.2.2 Identification of tumor-reactive T cells in glioma using marker for antigen-experience..... 83

4.2.3 A clinical platform for neo-epitope and TCR discovery in glioma patients: BRAINTuNE 85

4.3 Conclusion 86

5 References 87